You do not have permission to access this chart.
Please Sign Up or Login

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

27

Address:

Addex Therapeutics Ltd Chemin des Mines, 9 Geneva 1202 Switzerland

Website:

http://www.addextherapeutics.com

Phone:

41 22 884 1555

Leave a comment

Your email address will not be published. Required fields are marked *